Erythropoietin Stimulating Agents

Erythropoietin (EPO) is a glycoprotein hormone produced by the peritubular cells of the renal cortex. This hormone stimulates red blood cell production in response to low partial pressure of oxygen (pO2). Erythropoiesis-stimulating agents (ESAs), such as epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin , are pharmacologically synthesized, recombinant forms of EPO. ESAs are indicated for conditions associated with impaired red blood cell production. This educational activity highlights the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of ESAs, comparing them to the physiology of natural erythropoietin. Additionally, this discussion covers the FDA-issued box warnings, administration, and toxicity of ESAs. Understanding the intricate pharmacology of ESAs allows healthcare professionals to tailor treatment plans to individual patient needs. This activity emphasizes the critical role of the interprofessional healthcare team and aims to equip healthcare professionals with essential knowledge and tools to advance patient outcomes and care standards. This knowledge facilitates informed decision-making in prescribing ESAs and optimizing dosage regimens while minimizing adverse reactions, ultimately enhancing patient care.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.